Ask about this productRelated genes to: LASS6 antibody
- Gene:
- CERS6 NIH gene
- Name:
- ceramide synthase 6
- Previous symbol:
- LASS6
- Synonyms:
- -
- Chromosome:
- 2q24.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-04-30
- Date modifiied:
- 2016-10-05
Related products to: LASS6 antibody
Related articles to: LASS6 antibody
- Sphingolipids, particularly ceramide (Cer) and sphingomyelin (SM), are critical for cellular homeostasis, serving as both essential membrane components and key signaling molecules. This review systematically classifies sphingolipid disorders by organ system, emphasizing chain-length-dependent effects such as the pro-inflammatory role of C16-Cer versus the protective functions of C24-Cer in disease. - Source: PubMed
Publication date: 2026/03/09
Kong LiliShi JiaxinWang SiyuanHuang JiaqiGe YidongLi YvxuanLi KaiLangZhao MengxiangLi ZhiyouJin Xiaofeng - Autism spectrum disorder (ASD) is a heterogeneous neurological condition with an unclear etiology and pathogenesis. In recent years, studies have identified changes in lipid metabolism, inflammation, mitochondrial dysfunction, and mitophagy in patients with ASD. However, the specific interactions between these molecular signatures and their clinical applications in ASD remain largely unexplored. The aim of our study is to search for correlations between changes in gene and miRNA expression and the clinical characteristics of ASD. The investigation included a cohort of children with idiopathic ASD and healthy controls (HC). Diagnosis was established based on ADOS assessment (autism diagnostic observation schedule). Gene expression levels of sphingomyelin phosphodiesterases (SMPD1 and 5), ceramide synthases (CerS1 and 6), cyclooxygenase-2 (COX2), chitinase-3-like protein 1 (YKL40), and lysosome-associated membrane proteins 1 and 2 (LAMP1 and 2) were assessed using qPCR. The TaqMan assay was used for the quantification of miR-143-3p and miR-181a-5p. Our findings provide novel data on altered expression profiles of molecules related to lipid metabolism and LAMP1/2 in patients with ASD. We observed increased mRNA levels of CerS1, SMPD5, COX2, YKL40, LAMP1, and LAMP2 and decreased expression of miRNA-181a-5p in ASD patients compared to HC. Additionally, we identified a correlation between CerS1, CerS6, COX2, and miRNA-143-5p with ADOS scores. Multiple regression analysis revealed that 48.0% of the variance in the total ADOS score was explained by the combined effects of COX2, miRNA-143-3p, CerS1, CerS6 and age. These results provide new insights into the molecular alterations associated with ASD and may reinforce future studies aimed at clarifying their functional relevance. - Source: PubMed
Publication date: 2026/02/14
Gevezova MariaMaes MichaelPacheva IlianaMehterov NikolayIvanov ZdravkoTimova ElenaSpassieva StefkaBieberich ErhardKazakova MariaIvanov IvanSarafian Victoria - Metabolic diseases have increased worldwide in recent decades, mainly due to a sedentary lifestyle and an unhealthy diet, with diet identified as an important regulator of gut microbiota composition. The use of natural products, such as Crocus sativus tepals extract (CTE) could be a promising approach to alleviate metabolic disorders. The aim was to investigate the potential ameliorative mechanisms of CTE in metabolic disorders induced by a high-fat diet in an animal model, focusing on the composition of the gut microbiota and its relationship with the gut-liver axis. We analyzed liver-related biochemical and morphological parameters in mice fed a 60% fat diet for 14 weeks and orally treated with CTE during the last 5 weeks of the diet. In addition, jejunal and liver histology, intestinal barrier integrity, inflammation and oxidative stress, liver inflammation and lipid metabolism were investigated. The results showed that oral administration of CTE restored the composition of the gut microbiota and specifically promoted short-chain fatty acids-producing and anti-inflammatory bacterial genera. It also improved intestinal barrier integrity and reduced inflammation in the jejunum and liver, along with a suppression of Fas and CerS6 expression in the liver and a reduction in circulating free fatty acids and β-hydroxybutyrate levels. Our results indicate a possible link between the gut microbiota and the metabolic benefits of treatment with CTE, suggesting its therapeutic potential for the prevention or treatment of metabolic disorders. - Source: PubMed
Bursać BiljanaVratarić MilošGligorovska LjupkaBellachioma LuisaTeofilović AnaVojnović Milutinović DanijelaMorresi CamillaDamiani ElisabettaBacchetti TizianaDjordjevic Ana - To investigate the mechanism by which the CBX4-HDAC5-CERS6 axis regulates sphingolipid metabolism in acute myeloid leukemia (AML), with the goal of providing new theoretical foundations for the targeted therapy of AML. - Source: PubMed
Publication date: 2025/11/25
Ye RuifangSun MingweiHuang JixianSun LeiWu YaoZou XiangliTang Huanwen - Insulin-producing β-cells are destroyed in type 1 diabetes mellitus (T1DM), a chronic autoimmune disease that results in complete insulin insufficiency and metabolic dysfunction. According to a survival study that used p values, some hub genes are important for predicting and diagnosing illness. Scientists have inferred medicines to identify possible therapies that interact with the identified hub genes. The GSE10586 gene expression dataset from the Gene Expression Omnibus (GEO) was used for this investigation, which included 27 samples from 15 healthy controls and 12 diabetic patients. Normalization methods such as variance stabilization normalization (VSN) were used as part of the data pretreatment. A protein‒protein interaction (PPI) network was constructed, principal component analysis (PCA) was performed, heatmaps were created, and the Limma algorithm was used to analyze differential gene expression. Using DAVID v6.8 and KEGG pathway annotations, the functional enrichment of differentially expressed genes (DEGs) was evaluated. Furthermore, a computational study revealed CERS6 to be one of the potential hub genes. Four drugs, methotrexate, eliglustat, myriocin and statin, were the focus of further studies on the basis of predictions made via ChemSpider and PubChem database analysis. To determine the optimal binding positions of these drugs with CERS6, we used molecular docking techniques. The binding affinity of methotrexate was 8.48 kcal/mol, that of myriocin was 7.85 kcal/mol, that of eliglustat was - 6.62 kcal/mol, and that of serine was - 4.90 kcal/mol against the binding pocket's active residues. To determine how consistently each drug interacted with the CERS6 protein over time, molecular dynamics (MD) simulations were run. Throughout the simulation intervals, both medications were confirmed to be stable, with minor alterations in the CERS6 protein loop region. Therefore, the investigation of structure-based drug design has potential for identifying specific therapeutic targets. Ten hub genes were identified via network analysis of differentially expressed genes. These hub genes could serve as novel targets for T1DM detection, prognosis, and targeting. CERS6 exhibited the highest degree of interaction. Methotrexate, eliglustat, myriocin and statins were identified as potential drugs for CERS6. Overall, these findings provide valuable insights that could pave the way for new experimental strategies in T1DM therapy. - Source: PubMed
Publication date: 2025/12/01
Ayaz HassanHussain TajamulNawaz AsiaSuleman MuhammadAlrokayan SalmanOzsahin Dilber UzunMuhammad KhalidWaheed Yasir